WARREN, N.J., March  06, 2026  (GLOBE NEWSWIRE) -- Tevogen (&#34;Tevogen Bio Holdings Inc.&#34; or &#34;Company&#34;) (NASDAQ:TVGN).  Dear Shareholders,  As we continue executing on Tevogen&#39;s long-term strategy to evolve into a

TVGN

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Pursuing Strategic Acquisitions to Boost Revenue Growth

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>WARREN, N.J., March  06, 2026  (GLOBE NEWSWIRE) -- Tevogen (&amp;#34;Tevogen Bio Holdings Inc.&amp;#34; or &amp;#34;Company&amp;#34;) (NASDAQ:TVGN).  Dear Shareholders,  As we continue executing on Tevogen&amp;#39;s long-term strategy to evolve into a</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Tevogen is pursuing strategic acquisitions to bolster its immunotherapy and AI platforms, potentially generating over $50 million in annual revenues. This initiative aligns with their long-term growth strategy, focusing on sustainable healthcare solutions and operational efficiency, which could positively impact shareholder value.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Tevogen is evaluating potential acquisitions to enhance immunotherapy platforms.</li><li>Subsequent entities may generate over $50 million in annual revenues.</li><li>Strategic initiatives focus on sustainable growth and revenue generation.</li><li>Commitment to affordability and operational efficiency remains central.</li><li>Forward-looking statements indicate potential risks in execution and market conditions.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Microsoft (MSFT)</strong>: Part of Tevogen&#039;s technology partnerships for AI development.</li><li><strong>Databricks (N/A)</strong>: Supports Tevogen&#039;s cloud-based data services for drug development.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This article falls under Corporate Developments due to Tevogen&#039;s strategic acquisition plans, which directly influence its growth trajectory and market positioning.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Acquisition discussions could lead to shares appreciating upon confirmation.</li><li>Positive cash flow generation from subsidiaries expected to strengthen fundamentals.</li><li>Market reaction may increase based on revenue projections exceeding $50 million.</li><li>Investors should monitor for updates on due diligence and negotiations.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Tevogen is NASDAQ-listed as TVGN.</li><li>Potential acquisitions may yield over $50 million in annual revenues.</li><li>The company is committed to operational efficiency and shareholder value creation.</li><li>Tevogen has completed proof-of-concept trials for its T cell therapies.</li><li>Current strategic focus includes expanding immunotherapy and AI platforms.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish on TVGN as strategic acquisitions may enhance revenue and market position.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>WARREN, N.J., March  06, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=48eUqnM0Ive7O_WHgmM7wnYXOai1ptIPhFBTicIf-SUP6VfZtDSiaf4s_u1XjjuZD6_5NRbyd0ZvbgDPlIa4YQ==" rel="nofollow" target="_blank">Tevogen</a> ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TVGN">TVGN</a>).</p>  <p>Dear Shareholders,</p>  <p>As we continue executing on Tevogen's long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives.</p>  <p>Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time.</p>  <p>Based on preliminary evaluations, the combined entities under consideration may generate aggregate annual revenues in excess of $50 million. While these discussions remain subject to customary due diligence, negotiation, and definitive agreements, we believe the opportunity aligns with our disciplined growth strategy.</p>  <p>Tevogen was built on the belief that innovation and affordability are not mutually exclusive. As we expand, we remain committed to disciplined capital allocation, operational efficiency, and long-term shareholder value creation.</p>  <p>We appreciate your continued trust and support as we pursue strategic initiatives intended to strengthen Tevogen's financial foundation while advancing our mission of developing accessible immunotherapies.</p>  <p>Sincerely,</p>  <p>Dr. Ryan Saadi<br></br>Founder &amp; Chief Executive Officer<br></br>Tevogen</p>  <p><strong>About Tevogen</strong></p>  <p>Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.</p>  <p>Tevogen Bio, the company's lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio's pipeline spans virology, oncology, and neurology, with programs built on the company's proprietary ExacTcell&#x2122; platform.</p>  <p>Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.</p>  <p>Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen's mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.</p>  <p><strong>Forward Looking Statements</strong></p>  <p>This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transactions and the potential benefits of the transactions; Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.</p>  <p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transactions; the risk that the transactions may not be consummated on favorable terms or at all; the risk that the expected benefits of the transactions may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's most recent Annual Report on Form 10-K and subsequent filings with the SEC.</p>  <p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.</p>  <p><strong>Contacts</strong></p>  <p>Tevogen Bio Communications<br></br>T: 1 877 TEVOGEN, Ext 701 <br></br><a href="https://www.globenewswire.com/Tracker?data=IVT9mHqh1uKclFsLu1RGsRH135_hqCgBkCtPdlQqDfH5SSU3xB_1MDXKVnb9t19dXKztt2gK8qyftqB9W-rQcz0nPPRZT-r9dxm-11_uYUnTHfjPSsDqM4vs_For_Kji" rel="nofollow" target="_blank">Communications@Tevogen.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2NzU5MSM3NDcyNjA5IzIyODk5MTc="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZmRkNmU4MjEtOWQ4MS00N2M2LWFiNDMtMjQxYTBkNmY5YTQ0LTEzMDE0NjctMjAyNi0wMy0wNi1lbg==/tiny/Tevogen-Bio-Inc.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/679fef4d-f32f-46a2-9452-c31af5cf4597"><img src="https://ml.globenewswire.com/media/679fef4d-f32f-46a2-9452-c31af5cf4597/small/tevogen-logo-newswire-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a></p>

Tevogen is pursuing strategic acquisitions to bolster its immunotherapy and AI platforms, potentially generating over $50 million in annual revenues. This initiative aligns with their long-term growth strategy, focusing on sustainable healthcare solutions and operational efficiency, which could positively impact shareholder value.

Letter to Shareholders from CEO Dr. Ryan Saadi

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News